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Abstract
Visceral leishmaniasis (VL) is one of the most important tropical diseases worldwide. Although chemotherapy has been 
widely used to treat this disease, problems related to the development of parasite resistance and side effects associated with the 
compounds used have been noted. Hence, alternative approaches for VL control are desirable. Some methods, such as vector 
control and culling of infected dogs, are insuffi ciently effective, with the latter not ethically recommended. The development of 
vaccines to prevent VL is a feasible and desirable measure for disease control; for example, some vaccines designed to protect 
dogs against VL have recently been brought to market. These vaccines are based on the combination of parasite fractions or 
recombinant proteins with adjuvants that are able to induce cellular immune responses; however, their partial effi cacy and the 
absence of a vaccine to protect against human leishmaniasis underline the need for characterization of new vaccine candidates. 
This review presents recent advances in control measures for VL based on vaccine development, describing extensively studied 
antigens, as well as new antigenic proteins recently identifi ed using immuno-proteomic techniques.
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INTRODUCTION
Leishmaniasis is a disease complex caused by different 
species of protozoan parasites of the genus Leishmania(1). 
The disease causes high levels of morbidity and mortality 
worldwide, where approximately 1-1.5 million cases of 
tegumentary leishmaniasis (TL) and 0.2-0.5 million cases of 
visceral leishmaniasis (VL) are registered annually(2). VL is 
caused by parasites of the Leishmania donovani complex, 
including the species L. donovani and Leishmania infantum(3). 
In the Americas, VL is a zoonotic disease caused by L. infantum, 
where dogs are considered the main domestic reservoirs of the 
parasites(4) (5). In human VL, the outcomes of infection can vary 
from an asymptomatic and/or subclinical disease to a form with 
acute symptoms; the disease carries a high risk of mortality in 
the absence of an adequate treatment(6) (7).
Chemotherapy based on the administration of pentavalent 
antimonials has been used to treat VL; however, these products 
present problems related to their toxicity(8) (9) (10). Other 
drugs, such as pentamidine, miltefosine, and amphotericin 
B also present issues of toxicity and/or high cost(11) (12) (13) (14). 
Early diagnosis of VL could allow for more effective treatment 
of the disease; however, parasitological diagnosis, based on the 
direct observation of amastigote forms has low sensitivity and 
requires invasive collection procedures(15). The detection of 
Leishmania deoxyribonucleic acid (DNA) using the polymerase 
chain reaction (PCR) technique is highly specifi c; however, 
its sensitivity is variable(16) (17). Serological tests based on the 
detection of antileishmanial antibodies in patient serum samples 
are also employed for the diagnosis of VL; however, these 
are also associated with issues related to sensitivity and/or 
specifi city, depending on the antigens targeted(18) (19).
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Evidence of life-long immunity to leishmaniasis has also 
inspired the development of prophylactic vaccination protocols 
against the disease, although few have progressed beyond 
the experimental stage(14). An ideal vaccine candidate against 
leishmaniasis should be safe, affordable to the population, 
and able to induce both cluster of differentiation 4+ (CD4+) 
and cluster of differentiation 8+ (CD8+) T cell responses and 
long-term immunological memory, which could be boosted by 
natural infections, thus reducing the number of vaccine doses 
required. In addition, an ideal vaccine should be effective against 
different Leishmania species and stable at room temperature or 
at 4°C, to eliminate the need for storage at -20°C or -80°C(20). 
However, the induction and maintenance of long-lasting 
immunity and protection against different Leishmania species 
are very diffi cult to achieve, since the majority of candidate 
vaccines are composed of antigens that only offer species-
specifi c protection(21) (22) (23) (24) (25) (26).
Protective immunity against VL is based on the development 
of an antigen- and parasite-specific T-helper 1 (Th1)-type 
cellular response, primed by the production of interferon-gamma 
(IFN-γ), interleukin-2 (IL-2), interleukin-12 (IL-12), granulocyte 
macrophage colony-stimulating factor (GM-CSF), and other 
cytokines(27) (28) (29) (30) (31) (32). The induction of CD4+ Th1 cell 
responses against parasite antigens is crucial in controlling primary 
infection, when cytokines such as IFN-γ induce nitric oxide 
production by activated phagocytic cells able to kill internalized 
parasites(33) (34). Concomitantly to the role of CD4+ T cells, CD8+ 
T cells also contribute to protection against disease, and have an 
important role in controlling primary infections by increasing 
the Th1 response through a mechanism dependent on IFN-γ 
production(35). In contrast, cytokines such as interleukin-4 (IL-
4), interleukin-10 (IL-10), interleukin-13 (IL-13), interleukin-18 
(IL-18), and transforming growth factor beta (TGF-β) represent 
disease promoting molecules which inhibit the Th1 response, 
contributing to the deactivation of infected macrophages 
and, consequently, to the development of disease(36) (37) (38).
In recent years, proteomic screening studies have revealed a 
number of antigenic proteins specifi c to the Leishmania genus 
and frequently annotated as hypothetical proteins in genome 
databases. This review explores recent developments and discusses 
the prospects for vaccine development against VL, focusing on 
well-known antigens described in the literature, as well as the 
discovery of new antigens by immuno-proteomic approaches.
SECOND-GENERATION VACCINES 
AGAINST VISCERAL LEISHMANIASIS
Advances in recombinant DNA technology have led to the 
extensive study of several species- or stage-specifi c Leishmania 
molecules as candidate vaccines in the form of recombinant 
proteins. The major advantages of these candidates are their 
purity and the production yields achievable. Several proteins 
have been frequently investigated as candidate vaccines for the 
cutaneous form of leishmaniasis; however, few of these have 
been evaluated in mammalian VL models(39). Recombinant 
proteins have been evaluated as second-generation vaccines 
for VL with variable degrees of success, usually depending 
on the vaccine formulation and associated immune adjuvants, 
as well as the animal model used for testing. Amastigote and 
promastigote parasite antigens are the most common vaccine 
candidates tested.
Among amastigote-specifi c antigens tested for induction of 
immune protection against VL, the A2 antigen has emerged as 
an effective candidate. It is encoded by a multigene family that is 
abundantly expressed in the amastigote forms of some Leishmania 
species able to cause VL(40). Studies of the administration of 
recombinant A2 protein associated with immune adjuvants(41) (42) 
or as a DNA vaccine(43), as well as in attenuated non-replicative 
viruses(44), non-pathogenic bacteria(45), or non-virulent Leishmania 
tarentolae(46), have provided evidence of its protective effi cacy 
in mammalian models. In general, anti-A2 protective immunity 
is associated with the generation of parasite-specifi c IgG2a 
antibodies, as well as with the production of high levels of 
antileishmanial IFN-γ and low levels of IL-10 by T cells in 
recall response to the A2 protein or parasite extracts(40). Other 
amastigote-specifi c antigens that have been considered promising 
candidates for VL prevention include the cysteine proteinases 
(CP). These enzymes belong to the papain super-family, three 
classes of which (CPA, CPB, and CPC) have been identifi ed 
in Leishmania parasites. Studies have shown that recombinant 
CPB protein, in combination with an immune adjuvant or as 
a DNA vaccine, induced protection against Leishmania major 
infection in BALB/c mice(47). In another study, recombinant CPA/
CPB polyprotein vaccine was administered in association with 
poloxamer 407 as an adjuvant, and induced a protective response 
against L. major in BALB/c mice, which was more robust than 
the response induced by recombinant CPA and CPB proteins 
administered as separate individual antigens(48); however, these 
antigens were not tested as vaccines against VL.
In an evaluation of antigens expressed in promastigote forms 
of Leishmania parasites as vaccine candidates against VL, parasite 
surface antigen-2 (PSA-2), which comprises three polypeptides 
with molecular weights ranging from 50.0 to 96kDa(49), showed 
satisfactory results. This immunogen was able to induce 
protection against a Leishmania challenge in mice, through 
the development of a Th1-type response, when administered 
associated with Corynebacterium parvum as an adjuvant(50). 
Kinetoplastid membrane protein-11 (KMP-11), a highly 
conserved protein expressed in different Leishmania species, 
was also verifi ed as protective against L. donovani infection 
in hamsters(51) (52). In addition, the nucleoside hydrolase 36kDa 
(NH36) antigen was shown to be protective against Leishmania 
infantum, Leishmania mexicana, and Leishmania amazonensis 
species in BALB/c mice, indicating its potential as a heterologous 
vaccine to protect against different Leishmania species(53) (54).
It has been postulated that a formulation containing different 
Leishmania proteins expressed in both parasite stages should 
provide better results, in terms of a more effective and protective 
vaccine against VL(42) (55). The use of vaccines combining different 
proteins could provide the benefi ts of increased simplicity and 
reduced production costs, since it would only be necessary to 
produce a single vaccine to protect against different Leishmania 
species(56). However, few studies have evaluated chimeric 
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TABLE 1
Summary of vaccines against visceral leishmaniasis based on individual recombinant proteins or polyproteins.
Protein Infective species Model Remarks Reference
A2 L. infantum Beagle dog Partial protection Fernandes et al(40)
Aldolase L. donovani Hamster Partial protection Gupta et al(67)
Cysteine-peptidases L. infantum Beagle dog No protection Poot et al(68)
Cysteine-proteinase III L. infantum BALB/c mice Partial protection Khoshgoo et al(69)
Cyclophilin 1 L. infantum BALB/c mice High protection Santos-Gomes(70)
dp72 L. infantum BALB/c mice Partial protection Jaffe et al(71)
eIF2 L. donovani Hamster 65% protection Kushawcha(72)
HASPB1 L. donovani BALB/c mice 70%–90% protection Stager et al(26)
LCR1 L. infantum BALB/c mice Partial protection Wilson et al(73)
LdSir2HP L. donovani Hamster High protection Baharia et al(60)
LeishH1 L. infantum BALB/c mice High protection Agallou et al(27)
L3/L5 L. infantum BALB/c mice High protection Ramírez et al(74)
NH36 L. infantum BALB/c mice 80% protection Aguilar-Be et al(54)
ORFF L. donovani BALB/c mice Partial protection Tewary et al(75)
78 kDa protein L. donovani BALB/c mice High protection Joshi & Kaur(59)
A2/CPA/CPB* L. infantum BALB/c mice High protection Saljoughian et al(57)
KSAC* L. infantum C57BL/6 mice High protection Goto et al(61)
Leish-111f* L. infantum Beagle dog No protection Gradoni et al(76)
NS protein* L. donovani BALB/c mice High protection Coler et al(77)
Q protein* L. infantum Beagle dog 90% protection Molano et al(78)
8E/p21/SMT* L. donovani C57BL/6 mice High protection Duthie et al(79)
dp72: 72 kDa L. donovani protein; eIF2: eukaryotic initiation factor-2; HASPB1: hydrophilic acylated surface protein B; LCR1: complete conservation of an 
immunogenic gene; LdSir2HP: NAD+-dependent silent information regulatory-2 (SIR2 family or sirtuin) protein; LeishH1: Leishmania (L.) infantum histone 
H1; L3/L5: Leishmania major ribosomal proteins L3 (LmL3)/L5 (LmL5); NH36: nucleoside hydrolase 36 kDa; ORFF: open-reading frame; A2/CPA/CPB: 
A2/cysteine proteinase type II/ cysteine proteinase type I; KSAC: polyprotein vaccine formulated with monophosphoryl lipid A; NS protein: nucleoside 
hydrolase and a sterol 24-c-methyltransferase; 8E/p21/SMT: 8E/p21/sterol methyltransferase; L.: Leishmania. *Indicates polyprotein or chimeric vaccines.
vaccines aimed at protection against VL(25) (57), since the majority 
of reports have been of investigations of single antigens(14) (58) (59) (60). 
The development of a multi-antigenic vaccine requires 
an appropriate choice of the biological targets for use in 
its composition. In a recent study, a polyprotein vaccine 
formulated with monophosphoryl lipid A, KSAC, was shown 
to be immunogenic and effective in inducing protection 
against L. infantum and L. major in mice. KSAC is a chimeric 
protein composed of the Leishmania homolog of the receptor 
for activated C kinase (LACK), glycoprotein 63 kDa (gp63), 
thiol-specifi c-antioxidant (TSA), hydrophilic acylated surface 
protein B (HASPB), sterol 24-c-methyltransferase (SMT), 
KMP-11, A2, and CPB proteins. In models challenged with 
both Leishmania species, the protective response was associated 
with the production of high levels of IFN-γ, combined with low 
levels of IL-4 and a decreased antileishmanial IgG1 response(61). 
Another chimeric protein, Leish-111f, which is composed of a 
combination of TSA, stress inducible protein 1 (LmSTI-1), and 
the Leishmania homolog of the eukaryotic translation initiation 
factor (eIF4A), was also able to protect BALB/c mice against 
Leishmania infection, when administered in association with 
immune adjuvants(62).
Another fi eld that could be developed in relation to the 
discovery of new candidate VL vaccines is based on vector 
salivary proteins. To date, evidence indicates that salivary 
molecules able to induce a Th1-type response in immunized 
animals could create a protective immunological environment at 
the bite site, which could infl uence when parasites are injected, 
allowing control of the disease and concomitant promotion of 
Leishmania-specifi c immunity(63). The Th1-type immunological 
environment in response to these antigens at the bite site could 
promote a protective immune response against the parasite 
challenge. In this context, PdSP15, a 15-kDa salivary protein, 
which is a member of the family of small odorant binding proteins 
from Phlebotomus duboscqi, was evaluated as a candidate 
antigen against leishmaniasis in non-human primates(64). In 
addition, LJM19, an 11-kDa salivary protein of unknown function 
and LJL143, a 38-kDa salivary protein with anticoagulant 
activity(65), both of which are present in the saliva of Lutzomyia 
longipalpis, were shown to be protective against VL(66). Table 1 
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shows a summary of relevant vaccine candidates evaluated as 
individual recombinant protein or polyprotein vaccines against 
VL(67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79).
THE APPLICATION OF IMMUNO-PROTEOMIC 
APPROACHES TO THE IDENTIFICATION 
OF NEW LEISHMANIA ANTIGENS WITH 
POTENTIAL TO BE USED AS VISCERAL 
LEISHMANIASIS VACCINES
Immuno-proteomic approaches have been developed to 
identify new Leishmania proteins with distinct biological 
functions, such as new diagnostic markers, vaccine candidates, 
and/or potential drug targets(80) (81) (82). The use of antileishmanial 
antibodies obtained from infected mammalian hosts contributed 
to the refinement of these analyses, by assisting in the 
identifi cation of antigens recognized by the immune system 
during active disease(82) (83). Immuno-proteomic approaches 
usually involve protein preparation and separation by bi-
dimensional electrophoresis, followed by immunoblotting 
experiments, and subsequent identifi cation of protein spots by 
mass spectrometry (Figure 1). In a recent immuno-proteomic 







FIGURE 1. Experimental workfl ow for accurate identifi cation of antigenic proteins using bi-dimensional (2-DE) immunoblotting assays. The technical steps 
usually performed when an immuno-proteomic approach is applied are: 1) Preparation of total protein extracts from the parasite. 2) Isoelectric focusing and 
bi-dimensional SDS-PAGE. 3) Immunoblotting experiment. 4, 5, 6) Protein digestion and peptide extraction. 7, 8) Prepare and identify spots using MALDI-
TOF-TOF peptide mass mapping. 9) Database search to identify the antigenic proteins. 10) Identifi ed proteins. SDS-PAGE: Polyacrylamide gel electrophoresis. 
MALDI-TOF-TOF:  matrix-assisted laser desorption ionization/time-of-fl ight mass spectrometer.
serum samples of dogs developing VL(83). These proteins 
were analyzed in silico for epitope identifi cation, and the 
best antigenic determinants were employed in enzyme-linked 
immunosorbent assay (ELISA) assays aiming to identify 
antigenic peptides of interest for the serodiagnosis of canine 
disease. The authors speculated about the use of these candidates 
as vaccines in future assays, owing to the existence of putative-T 
cell motifs in the antigens. In another immuno-proteomic 
approach, developed using protein extracts from the stationary 
promastigote and amastigote-like stages of L. infantum, several 
specific promastigote (Table 2) and amastigote (Table 3) 
hypothetical proteins were identifi ed in serum samples from 
dogs with asymptomatic and/or symptomatic VL(82).
Some of these proteins have already been validated as 
candidate VL vaccines (Table 4). These antigens were selected 
because they are conserved among different Leishmania species, 
but are not present in other Trypanosomatidae or in mammalian 
hosts. In addition, the selected antigens contain specifi c CD4+ 
and CD8+ T cell epitopes. In this context, the protective effi cacy 
against L. infantum infection of LiHyp1, a Leishmania protein 
belonging to the super-oxygenase family, was evaluated in BALB/c 
mice. Immunization using the recombinant LiHyp1 protein 
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TABLE 3
Hypothetical proteins identifi ed in amastigote-like Leishmania infantum by an immuno-proteomic approach using serum samples from dogs 
with asymptomatic and symptomatic VL. 
Sera classa Identifi ed speciesb Accession numberc Mr (kDa) (exp/pred)d pI (exp/pred)e
Asymptomatic L. infantum XP_001467126.1 19/21 5.25/6.60
Asymptomatic L. infantum XP_001468941.1 37/36 6.53/5.72
Symptomatic L. infantum XP_001568117.1 13/35 5.23/5.25
Symptomatic L. infantum AF398369_1 14/13 6.55/5.27
Symptomatic L. major XP_001684096.1 18/19 4.65/9.75
Symptomatic L. infantum XP_001468309.1 25/82 5.82/6.41
Symptomatic L. braziliensis XP_001564596.1 28/94 5.02/5.58
Symptomatic L. infantum XP_001467567.1 25/25 6.40/8.40
Symptomatic L. major XP_843545.1 41/45 6.18/6.21
Symptomatic L. braziliensis XP_001564657.1 46/52 6.25/10.09
Symptomatic L. infantum XP_001465588 50/45 6.09/4.04
Symptomatic L. braziliensis XP_001564657.1 60/52 6.12/10.09
Symptomatic L. infantum XP_001463134.1 75/72 5.40/8.95
Symptomatic L. infantum XP_001466114.1 72/108 6.25/6.12
Symptomatic and asymptomatic L. major XP_888524.1 50/54 5.35/5.20
Symptomatic and asymptomatic L. infantum XP_001469969.1 58/86 5.25/5.52
Symptomatic and asymptomatic L. braziliensis XP_001568364.1 68/71 4.85/5.89
VL: visceral leishmaniasis; Mr (Kda): molecular weight; pl: isoelectric point; exp/pred: expected/predicted; L.: Leishmania; NCBI: National Center for 
Biotechnology Information. aSerum samples from dogs with VL. bIdentifi ed species. cNCBI Accession number. dExpected/predicted Mr. eExpected/predicted pI.
TABLE 2
Hypothetical proteins identifi ed in Leishmania infantum stationary promastigotes by an immuno-proteomic approach using serum 
samples from dogs with asymptomatic and symptomatic VL. 
Sera classa Identifi ed speciesb Accession numberc Mr (kDa) (exp/pred)d pI (exp/pred)e
Asymptomatic L. major CAJ09012.1 23/24 5.88/6.44
Asymptomatic L. braziliensis XP_001567688.1 36/72 6.21/6.33
Asymptomatic L. infantum XP_001466647.1 42/41 5.05/4.89
Symptomatic L. infantum XP_001463668.1 18/23 4.81/5.97
Symptomatic L. braziliensis XP_001564693.1 21/24 5.55/10.64
Symptomatic L. major XP_001684884.1 21/21 6.20/6.60
Symptomatic L. braziliensis XP_001565846.1 22/35 6.45/7.68
Symptomatic L. major XP_001686061.1 24/37 4.52/9.17
Symptomatic L. braziliensis XP_001568689.1 27/24 6.80/8.89
Symptomatic L. major XP_888524.1 50/54 5.35/5.20
Symptomatic and asymptomatic L. braziliensis XP_001568117.1 13/35 5.23/5.25
Symptomatic and asymptomatic L. major XP_001682223.1 12/59 5.85/5.64
Symptomatic and asymptomatic L. major XP_001684096.1 18/19 4.65/9.75
Symptomatic and asymptomatic L. infantum XP_001468309.1 25/82 5.82/6.41
Symptomatic and asymptomatic L. braziliensis XP_001568364.1 68/71 4.85/5.89
VL: visceral leishmaniasis; Mr (Kda): molecular weight; pl: isoelectric point; exp/pred: expected/predicted; L.: Leishmania; NCBI: National Center for 
Biotechnology Information. aSerum samples from dogs with VL. bIdentifi ed species. cNCBI Accession number. dExpected/predicted Mr. eExpected/predicted pI.
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TABLE 4
Leishmania-specifi c hypothetical proteins validated as vaccine candidates for visceral leishmaniasis.
Protein Accession number Mr (kDa)/pI Biological application Reference(s)
LiHyp1 XP_001468941.1 36.6/5.72 Vaccine/Diagnosis [14]
LiHyp6 XP_001467126.1 21.4/6.60 Vaccine/Diagnosis [55]
LiHyD XP_001468360.1 36.5/9.49 Vaccine/Diagnosis [31] [91]
LiHyT XP_001465138.1 36.4/10.58 Vaccine [32] [55]
LiHyV XP_888524.1 54.0/5.16 Vaccine/Diagnosis [84]
Mr: molecular weight; pI: isoeletric point. LiHyp1: Leishmania infantum hypothetical protein 1; LiHyp6: Leishmania infantum hypothetical protein 6; 
LiHyD: Leishmania infantum hypothetical protein D; LiHyT: Leishmania infantum hypothetical protein T; LiHyV: Leishmania infantum hypothetical protein V.
plus saponin adjuvant induced a Th1 immune response in the 
vaccinated animals, which was primed by protein- and parasite-
specifi c IFN-γ, IL-12, and GM-CSF production, combined 
with the presence of low levels of IL-4 and IL-10. In addition, 
the protected animals displayed signifi cant reductions in the 
number of parasites in their livers, spleens, bone marrow, and 
draining lymph nodes, compared with that in control groups. 
The protection was correlated with parasite-specific and 
dependent IFN-γ production, mainly by CD4+ T cells, which 
were the major source of IFN-γ in these animals(14).The same 
immune profi le was found when the hypothetical LiHyD(31), 
LiHyT(32), LiHyp6(55), and LiHyV(84) proteins were evaluated as 
vaccine candidates. In all cases, the antigens were shown to be 
protective against infection, since vaccinated and challenged 
animals presented signifi cantly lower parasite levels in evaluated 
organs compared with control groups. In addition, vaccinated 
and challenged animals demonstrated predominantly IL-12 
driven IFN-γ production (also mediated mainly by CD4+ T cells) 
against parasite proteins, whereas unprotected controls showed 
high levels of anti-Leishmania IgG1 antibodies and a parasite 
mediated IL-4 and IL-10 response.
An aspect that should be considered when evaluating the 
effi cacy of a vaccine is the use of adjuvants. Although recombinant 
protein-based vaccines offer considerable advantages in terms 
of safety, standardization, purity, and production costs, they 
generally present limited immunogenicity and require the use of 
immune adjuvants(85). It is generally accepted that the adjuvants 
used in leishmaniasis vaccine formulations should be able to 
induce a Th1 response, and some adjuvants are capable of this, 
including recombinant IL-12, saponin, BCG, monophosphoryl 
lipid A (MPL), CpG, recombinant virus, and others(86) (87). The 
induction of IL-12 is critical for vaccine effi ciency and many 
of these adjuvants activate the innate immune response via 
Toll-like receptors (TLR), also infl uencing acquired immune 
responses(88). Signifi cant protection is not usually achieved 
when animals are immunized with recombinant proteins in the 
absence of adjuvants. These fi ndings have been corroborated by 
studies evaluating other well-known protective antigens against 
leishmaniasis(31) (32) (40) (54).
The concept of cross-protective vaccines is based on the 
presence of common antigens among pathogens and on the 
ability of formulated vaccines to elicit cellular immunity(89). 
Since multiple Leishmania species are distributed in common 
geographical areas, it would be desirable to develop vaccines 
capable of inducing protection against more than one parasite 
species(90). In this context, LiHyT, which was fi rstly identifi ed, 
in L. infantum(32) as protective against this species, was also 
shown to confer protection in BALB/c mice against L. major and 
L. braziliensis. Mice immunized with LiHyT and saponin as an 
adjuvant, developed a robust Th1 immune response, which was 
responsible for the induction of signifi cant reductions of parasite 
load in the tissues and organs evaluated(84). This cross-protective 
immunity was also found when another hypothetical protein, 
rLiHyD, was used as an antigen with saponin as an adjuvant(91).
As described, the use of chimeric vaccines containing 
multiple proteins and/or polypeptides could provide more robust 
protective effi cacy against various Leishmania species(61) (76) (78). 
In this context, three recombinant proteins were combined in a 
vaccine and tested for their protective effects against L. infantum 
infection. These proteins are expressed in both the promastigote 
and amastigote stages of the parasites, and their combination 
was able to induce pronounced parasite-specifi c IFN-γ, IL-
12, and GM-CSF responses in immunized mice, which was 
maintained after challenge. The infected and vaccinated animals 
showed signifi cant reductions in parasite burden in the various 
organs evaluated compared with control mice, the protection 
being associated with IL-12-dependent IFN-γ production 
against parasite extracts, and correlated with the induction 
of antileishmanial nitrite production. More importantly, this 
polyprotein vaccine was able to induce a more robust Th1 
response associated with better control of parasite dissemination 
in the organs of the vaccinated animals, compared with the use 
of the individual recombinant proteins(55).
CONCLUSIONS
Effective prophylactic measures to control VL are 
imperative. Such measures include the design of vaccines, 
which is the most economical way to control neglected 
diseases. An ideal vaccine candidate should be able to induce 
robust antileishmanial Th1 immunity, be parasite-specifi c (to 
avoid adverse effects in mammalian hosts), and exhibit a high 
degree of homology between different Leishmania species. 
Hypothetical proteins, considered unknown molecules until 
their recognition by the immune system of infected mammalian 
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hosts, could be considered for this purpose and explored for use 
in the prevention of VL. In addition, the development and use 
of new technologies, such as reverse vaccinology, to identify 
novel candidate VL vaccines should be also considered.
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